[1] McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018;24:4846–61. https://doi.org/10.3748/wjg.v24.i43.4846.
[2] Soldan M. Pancreatic cancer screening. Rev Colégio Bras Cir 2017;44:109–11. https://doi.org/10.1590/0100-69912017002015.
[3] Åkerberg D, Ansari D, Andersson R, Tingstedt B. The Effects of Surgical Exploration on Survival of Unresectable Pancreatic Carcinoma: A Retrospective Case-Control Study. J Biomed Sci Eng 2017;10:1–9. https://doi.org/10.4236/jbise.2017.101001.
[4] Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, et al. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583–8. https://doi.org/10.3892/mco.2017.1179.
[5] Grützmann R. Epidemiology, Treatment, and Outcome of Pancreatic Cancer. Mol. Diagn. Treat. Pancreat. Cancer, Elsevier; 2014, p. 3–9. https://doi.org/10.1016/B978-0-12-408103-1.00001-7.
[6] Zhou B, Xu J-W, Cheng Y-G, Gao J-Y, Hu S-Y, Wang L, et al. Early detection of pancreatic cancer: Where are we now and where are we going?: Early detection of pancreatic cancer. Int J Cancer 2017;141:231–41. https://doi.org/10.1002/ijc.30670.
[7] Aceto N, Toner M, Maheswaran S, Haber DA. En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. Trends Cancer 2015;1:44–52. https://doi.org/10.1016/j.trecan.2015.07.006.
[8] Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. J Clin Oncol 2012;30:525–32. https://doi.org/10.1200/JCO.2010.33.3716.
[9] Mader S, Pantel K. Liquid Biopsy: Current Status and Future Perspectives. Oncol Res Treat 2017;40:404–8. https://doi.org/10.1159/000478018.
[10] Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol 2019;20:21–37. https://doi.org/10.1038/s41580-018-0045-7.
[11] Abba M, Patil N, Leupold J, Allgayer H. MicroRNA Regulation of Epithelial to Mesenchymal Transition. J Clin Med 2016;5:8. https://doi.org/10.3390/jcm5010008.
[12] Krebs MG, Hou J-M, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. J Thorac Oncol 2012;7:306–15. https://doi.org/10.1097/JTO.0b013e31823c5c16.
[13] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods 2001;25:402–8. https://doi.org/10.1006/meth.2001.1262.
[14] Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther 2018;17:1147–55. https://doi.org/10.1158/1535-7163.MCT-17-0646.
[15] Panth KM, van den Beucken T, Biemans R, Lieuwes NG, Weber M, Losen M, et al. In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Sci Rep 2016;6:22198. https://doi.org/10.1038/srep22198.
[16] Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, et al. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med 2012;30:896–904. https://doi.org/10.3892/ijmm.2012.1071.
[17] Poruk KE, Valero V, Saunders T, Blackford AL, Griffin JF, Poling J, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 2016;264:1073–81. https://doi.org/10.1097/SLA.0000000000001600.
[18] Gasparini-Junior JL, Fanelli MF, Abdallah EA, Chinen LTD. EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION. ABCD Arq Bras Cir Dig São Paulo 2019;32. https://doi.org/10.1590/0102-672020190001e1433.
[19] Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate Filaments as Effectors of Cancer Development and Metastasis: A Focus on Keratins, Vimentin, and Nestin. Cells 2019;8:497. https://doi.org/10.3390/cells8050497.
[20] Zhou Y-F, Xu W, Wang X, Sun J-S, Xiang J-J, Li Z-S, et al. Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma. World J Gastroenterol 2014;20:13172–7. https://doi.org/10.3748/wjg.v20.i36.13172.
[21] Wei T, Zhang X, Zhang Q, Yang J, Chen Q, Wang J, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Lett 2019;452:237–43. https://doi.org/10.1016/j.canlet.2019.03.009.
[22] Briem E, Budkova Z, Sigurdardottir AK, Hilmarsdottir B, Kricker J, Timp W, et al. MiR-203a is differentially expressed during branching morphogenesis and EMT in breast progenitor cells and is a repressor of peroxidasin. Mech Dev 2019;155:34–47. https://doi.org/10.1016/j.mod.2018.11.002.
[23] Chen Q-F, Kong J-L, Zou S-C, Gao H, Wang F, Qin S-M, et al. LncRNA LINC00342 regulated cell growth and metastasis in non-small cell lung cancer via targeting miR-203a-3p. Eur Rev Med Pharmacol Sci 2019;23:7408–18. https://doi.org/10.26355/eurrev_201909_18849.